Loading...
Market
What will be Gilead Sciences' next major acquisition by end of 2024?
2
Resolution / Starting Odds
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Official announcements from Gilead Sciences and financial news sources like Bloomberg or Reuters
Story
Gilead's Livdelzi Gains Accelerated FDA Approval for Primary Biliary Cholangitis
Aug 14, 2024, 06:06 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Gilead Sciences for its liver disease treatment, Livdelzi (Seladelpar). This approval is specifically for the treatment of primary biliary cholangitis (PBC), an autoimmune liver disease that primarily affects women. The drug, which demonstrated significant improvements in liver disease markers and pruritus, was acquired through Gilead's $4.3 billion buyout of CymaBay Therapeutics earlier this year.
View original story
Similar markets
Below $27.1 billion • 25%
$27.1 billion to $27.3 billion • 25%
$27.31 billion to $27.5 billion • 25%
Above $27.5 billion • 25%
A cancer diagnostics company • 25%
A gene sequencing company • 25%
A biotech company unrelated to cancer diagnostics • 25%
No major acquisition • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
No new partnership • 25%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Yes • 50%
No • 50%
Cancer Treatment • 25%
Neurology Treatment • 25%
Immunology Treatment • 25%
Other Treatment • 25%